Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29592689 | 1.00 | POLB (0.52) | POLBCA12CA9MAOBMAOA | |
| SCHEMBL6509784 | 0.90 | SMN1; SMN2 (0.49) | MAOBSMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL27491194 | 0.85 | CA12 (0.48) | POLBCA12CA9MAOBMAOA | |
| SCHEMBL655464 | 0.85 | CA12 (0.56) | POLBCA12CA9MAOBMAOA | |
| SCHEMBL4253620 | 0.84 | MAOB (0.66) | CA12CA9MAOBSMN1; SMN2MAPT | |
| SCHEMBL7672880 | 0.84 | CA12 (0.69) | POLBCA12CA9MAOBMAOA | |
| SCHEMBL30595105 | 0.84 | CA12 (0.69) | POLBCA12CA9MAOBMAOA | |
| SCHEMBL14423946 | 0.83 | CA12 (0.57) | POLBCA12CA9MAOBMAOA | |
| SCHEMBL16732780 | 0.82 | CA12 (0.46) | POLBCA12CA9MAOBMAOA | |
| SCHEMBL16943491 | 0.82 | CA12 (0.52) | POLBCA12CA9MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143705-A | Benzofuran lymph specific tyrosine phosphatase inhibitor and preparation method and application thereof | 山东大学 | 2024-12-17 | — | — | CN | claimed |
| CN-118813733-A | Biocatalysis method for preparing vilazodone intermediate | 广东东阳光药业股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118745163-A | Benzofuran compound, preparation method and application thereof, and PDGFR kinase inhibitor | 四川省医学科学院·四川省人民医院 | 2024-10-08 | — | — | CN | claimed |
| WO-2014061004-A2 | PROCESS FOR THE PREPARATION OF VILAZODONE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2014-04-24 | — | — | WO | claimed |
| CN-114401960-B | Glue degradation agent and using method thereof | NOVARTIS AG (CH) | 2026-05-26 | — | — | CN | disclosed |
| EP-4695240-A2 | CYCLIC VINYL SULFONE WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260010085-A1 | NON-MAGNETIC ONE-COMPONENT DEVELOPING TONER AND METHOD FOR PRODUCING NON-MAGNETIC ONE-COMPONENT DEVELOPING TONER | KYOCERA DOCUMENT SOLUTIONS INC. (JP) | 2026-01-08 | — | — | US | disclosed |
| CN-119822964-A | Synthesis method of visible light-induced copper-catalyzed diarylamine compound | 铜陵学院 | 2025-04-15 | — | — | CN | disclosed |
| CN-119504380-A | Liquid stabilizer for nitrate compound and preparation method thereof | 南京理工大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-119462394-A | Selective controllable synthesis method of two types of alkyl aromatic amine compounds | 铜陵学院 | 2025-02-18 | — | — | CN | disclosed |
| EP-3719577-B1 | TONER BINDER AND TONER | SANYO CHEMICAL IND LTD (JP) | 2025-01-01 | — | — | EP | disclosed |
| CN-119143705-A | Benzofuran lymph specific tyrosine phosphatase inhibitor and preparation method and application thereof | 山东大学 | 2024-12-17 | — | — | CN | disclosed |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-10-13 | — | — | US | disclosed |
| WO-2005080367-A1 | EP2 RECEPTOR AGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005032594-A2 | ALKYLATORS LINKED TO POLYAMIDES AS DNA BINDING AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| US-5977112-A | Process of making substituted benzofurans | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-11-02 | — | — | US | disclosed |
| US-5723614-A | Benzofurans | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | POLB 3603/4885CA12 1985/4885CA9 1823/4885 |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | POLB 3171/4885CA12 2051/4885CA9 1812/4885 |
| US-20260010085-A1 | NON-MAGNETIC ONE-COMPONENT DEVELOPING TONER AND METHOD FOR PRODUCING NON-MAGNETIC ONE-COMPONENT DEVELOPING TONER | PSMD2, PSMD1, SMC4 | POLB 3615/4885CA12 1203/4885CA9 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.